Large-Cap Stocks Surge 11-25%: Earnings Fuel Rally

Ten large-cap stocks posted impressive gains between February 16-20, with returns ranging from 11% to over 25%. The rally was primarily fueled by better-than-expected quarterly earnings reports across multiple sectors. First Majestic Silver led the pack with a 25.23% surge after reporting strong adjusted EPS, while Omnicom Group jumped 22.52% on solid sales and a massive $5 billion buyback announcement.

Healthcare and technology names also featured prominently, with Moderna gaining nearly 20% after the FDA agreed to review its seasonal influenza vaccine. Garmin and Figma both delivered strong quarterly results accompanied by optimistic future guidance that exceeded analyst expectations.

The financial sector saw Global Payments rise 19.52% following positive earnings and its own substantial buyback program. Even cryptocurrency-exposed Coinbase managed an 11.32% gain despite maintaining a neutral analyst rating, suggesting broader market optimism.

What's notable is that these weren't speculative small-caps but established large-cap companies, indicating institutional money flowing into quality names with concrete fundamental improvements rather than speculative momentum plays.

For investors, this concentrated burst of large-cap strength signals that market leadership may be broadening beyond the typical tech megacaps. When companies across silver mining, advertising, healthcare, and payments all post double-digit weekly gains, it suggests underlying market health rather than sector-specific speculation.

The buyback announcements from Omnicom and Global Payments are particularly significant because they indicate management confidence in future cash flows. Share repurchases can provide ongoing support for stock prices while returning value to shareholders, making these moves more substantive than one-time earnings beats.

However, the patent lawsuit between BioNTech and Moderna introduces complexity to the healthcare narrative. While Moderna gained on vaccine news, the legal challenge could create uncertainty around its next-generation COVID vaccine pipeline, reminding investors that biotech investments carry unique regulatory and intellectual property risks.

Most importantly, several companies provided guidance well into 2026, suggesting this isn't just a quarter-over-quarter improvement but potentially sustained growth trajectories. Garmin and Figma's multi-year outlooks give investors visibility beyond immediate results, though they also set high expectations that must be met.